Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.38 |
| ▸ | MRGPRX1 | Q96LB2 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370619 | 0.88 | MEN1 (0.41) | MEN1KMT2AEGFRHSD11B1NR1I2 | |
| SCHEMBL5196093 | 0.86 | KMT2A (0.50) | MEN1KMT2AEGFRTRPA1MRGPRX1 | |
| SCHEMBL3488162 | 0.84 | MRGPRX1 (0.44) | MEN1KMT2AEGFRTRPA1MRGPRX1 | |
| SCHEMBL30377367 | 0.78 | SCN9A (0.40) | MEN1KMT2AEGFRHSD11B1NR1I2 | |
| SCHEMBL16378820 | 0.75 | KMT2A (0.56) | MEN1KMT2AEGFRTRPA1MRGPRX1 | |
| SCHEMBL2140667 | 0.75 | HSD11B1 (0.43) | HSD11B1NR1I2EPAS1HSD11B2 | |
| SCHEMBL1456975 | 0.73 | KMT2A (0.50) | MEN1KMT2AEGFRTRPA1MRGPRX1 | |
| SCHEMBL30374325 | 0.73 | KMT2A (0.50) | MEN1KMT2AEGFRTRPA1MRGPRX1 | |
| SCHEMBL14430205 | 0.73 | SCN9A (0.38) | MEN1KMT2AEGFRCYP1A2CYP2C19 | |
| SCHEMBL13970688 | 0.72 | EPAS1 (0.49) | HSD11B1NR1I2EPAS1ALDH1A1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124498-A1 | Halobenzyl substituted phenylaceto esters and amides and use thereof for prevention of harmful organisms | BAYER CROPSCIENCE AG (DE) | 2005-06-09 | — | — | US | disclosed |
| EP-1185505-B1 | METHOD OF PRODUCING METHOXYIMINO ACETIC AMIDE | BAYER CROPSCIENCE AG (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-6660872-B1 | In high yields | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1185505-A1 | METHOD OF PRODUCING METHOXYIMINO ACETIC AMIDE | Bayer Aktiengesellschaft (DE) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000071504-A1 | METHOD OF PRODUCING METHOXYIMINO ACETIC AMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124498-A1 | Halobenzyl substituted phenylaceto esters and amides and use thereof for prevention of harmful organisms | HDHD5, GNPAT, PGLS | MEN1 4472/4885KMT2A 1592/4885EGFR 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.